In Q2 2026, Bausch Health demonstrated operational resilience with revenue gains driven by its Salix pharmaceutical segment and Solta Medical aesthetic devices. The company manages a complex business model across multiple therapeutic areas including gastrointestinal, neuroscience, dermatology, and eye health. While diversified revenue streams mitigate competitive pressures, Bausch's financial health is constrained by substantial debt. Continued focus on clinical development, licensing partnerships, and effective revenue recognition amid regulatory pricing pressures will be critical to sustaining growth and cash flow.